Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083590 · ClinicalTrials.gov registry record · Phase 2
Huperzine A in Alzheimer's Disease
A Phase 2 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00083590 is a Phase 2 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 150 participants.
The verdict
NCT00083590, a Phase 2 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The present study will evaluate the safety and efficacy of the Chinese herb huperzine A in the treatment of Alzheimer's disease (AD) in a randomized controlled trial of its effect on cognitive function.
Interventions
- DRUG Huperzine A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083590
The ClinicalTrials.gov registry entry for NCT00083590 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Huperzine A is the first listed.
NCT00083590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083590 about?
NCT00083590 is a clinical study titled "Huperzine A in Alzheimer's Disease". The present study will evaluate the safety and efficacy of the Chinese herb huperzine A in the treatment of Alzheimer's disease (AD) in a randomized controlled trial of its effect on cognitive function.
What is the current status of trial NCT00083590?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2004-04. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00083590?
The interventions under investigation include: Huperzine A (DRUG).
Who is sponsoring clinical trial NCT00083590?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.